| Previous Close | 81.50 |
| Open | 81.50 |
| Bid | 76.00 |
| Ask | 81.00 |
| Strike | 40.00 |
| Expire Date | 2021-04-16 |
| Day's Range | 81.50 - 81.50 |
| Contract Range | N/A |
| Volume | 1 |
| Open Interest | N/A |
- Zacks
Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership
Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.
- Barrons.com
CRISPR Therapeutics Is Upgraded After $900 Million Deal
Jefferies analyst Maury Raycroft raised his rating on the stock to Buy from Hold and lifted his target for the share price to $172 from $165.
- Motley Fool
Vertex Pharmaceuticals Raises Bet on CRISPR Therapeutics
The relationship between Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) is taking another big step forward. On Tuesday morning, the collaboration partners amended their agreement regarding CTX001 in a way that places more risk on Vertex's shoulders. CRISPR Therapeutics and Vertex had already agreed to co-commercialize and co-develop CTX001, an experimental gene therapy for patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT).
